Improved coronary thrombolysis by tissue-type plasminogen activator in the presence of BAY U 3405.
The effect of BAY U 3405 (3 mg/kg i.v.) was tested on recombinant tissue-type plasminogen activator (rt-PA)-induced thrombolysis of an experimentally induced coronary thrombosis in anaesthetized dogs. BAY U 3405, given immediately before an rt-PA infusion, reduced time to reperfusion by more than 50% compared with vehicle-treated controls (P less than 0.01). After cessation of the rt-PA infusion, BAY U 3405 reduced the reocclusion rate compared to controls (P less than 0.05). These results show that BAY U 3405 improves rt-PA-induced coronary thrombolysis in a canine model.
Rounding
H P
HP
Institut für Pharmakologie, Bayer AG, Wuppertal, F.R.G.
Fiedler
V B
VB
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002227:Carbazoles / Q000378:metabolism / Q000494:pharmacology*; D003328:Coronary Thrombosis / Q000188:drug therapy*; D004285:Dogs; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D007262:Infusions, Intravenous; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use; D013449:Sulfonamides / Q000378:metabolism / Q000494:pharmacology*; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*
D002227:Carbazoles; D011994:Recombinant Proteins; D013449:Sulfonamides; D010959:Tissue Plasminogen Activator; C063119:ramatroban